Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonard R Friedland

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Vaccine|November 8, 2017
Letter to EditorPhilip S Watson, Leonard R Friedland
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 19, 2019
Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal diseasePhilip S Watson, Patricia L Novy, Leonard R Friedland
Vaccine|June 9, 2006
Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 yearsSteven Black, Leonard R Friedland, Anne Schuind, et al.
Human Vaccines|October 20, 2009
Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adultsWayde M Weston, Vijayalakshmi Chandrashekar, Leonard R Friedland, et al.
Vaccine|December 8, 2010
Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administrationWayde M Weston, Leonard R Friedland, Xiangfeng Wu, et al.
Vaccine|January 4, 2012
Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trialsWayde M Weston, Leonard R Friedland, Xiangfeng Wu, et al.
Vaccine|September 28, 2011
Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccineWayde Weston, Marc Messier, Leonard R Friedland, et al.
Current Opinion in Immunology|July 30, 2017
Towards an evidence based approach for the development of adjuvanted vaccinesDerek T O'Hagan, Leonard R Friedland, Emmanuel Hanon, et al.
Annals of Medicine|November 28, 2017
Understanding modern-day vaccines: what you need to knowVolker Vetter, Gülhan Denizer, Leonard R Friedland, et al.
Vaccine|December 2, 2008
Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of ageMark Blatter, Leonard R Friedland, Wayde M Weston, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Vaccine|November 8, 2017
Letter to EditorPhilip S Watson, Leonard R Friedland
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 19, 2019
Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal diseasePhilip S Watson, Patricia L Novy, Leonard R Friedland
Vaccine|June 9, 2006
Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 yearsSteven Black, Leonard R Friedland, Anne Schuind, et al.
Human Vaccines|October 20, 2009
Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adultsWayde M Weston, Vijayalakshmi Chandrashekar, Leonard R Friedland, et al.
Vaccine|December 8, 2010
Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administrationWayde M Weston, Leonard R Friedland, Xiangfeng Wu, et al.
Vaccine|January 4, 2012
Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trialsWayde M Weston, Leonard R Friedland, Xiangfeng Wu, et al.
Vaccine|September 28, 2011
Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccineWayde Weston, Marc Messier, Leonard R Friedland, et al.
Current Opinion in Immunology|July 30, 2017
Towards an evidence based approach for the development of adjuvanted vaccinesDerek T O'Hagan, Leonard R Friedland, Emmanuel Hanon, et al.
Annals of Medicine|November 28, 2017
Understanding modern-day vaccines: what you need to knowVolker Vetter, Gülhan Denizer, Leonard R Friedland, et al.
Vaccine|December 2, 2008
Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of ageMark Blatter, Leonard R Friedland, Wayde M Weston, et al.
Pageof 4